ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)

Completed

Conditions: Crohn's Disease

First Posted Date: 2023-11-13

Last Posted Date: 2024-06-03

Lead Sponsor: AbbVie

Target Recruit Count: 53

Registration Number: NCT06126146

Locations: 🇬🇧
Guys and St Thomas NHS Foundation Trust /ID# 258986, London, London, City Of, United Kingdom
🇬🇧
NHS Lothian /ID# 260901, Edinburgh, United Kingdom
🇬🇧
The Royal London Hospital /ID# 259047, London, United Kingdom

and more 2 locations

A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain

Recruiting

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2023-11-09

Last Posted Date: 2024-11-04

Lead Sponsor: AbbVie

Target Recruit Count: 132

Registration Number: NCT06125795

Locations: 🇪🇸
Hospital de Cabueñes /ID# 263307, Gijón, Asturias, Spain
🇪🇸
Hospital Universitario Dr. Negrin /ID# 258285, Las Palmas de Gran Canaria, Las Palmas, Spain
🇪🇸
Hospital Clinico Universitario Virgen de la Arrixaca /ID# 262173, El Palmar, Murcia, Spain

and more 17 locations

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

Phase 3

Active, not recruiting

Conditions: Vitiligo

Interventions: Drug: Upadacitinib
Drug: Placebo
Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

First Posted Date: 2023-11-07

Last Posted Date: 2024-12-13

Lead Sponsor: AbbVie

Target Recruit Count: 614

Registration Number: NCT06118411

Locations: 🇺🇸
Joseph Raoof Md,Inc /Id# 260055, Encino, California, United States
🇺🇸
Alliance Dermatology and Mohs Center /ID# 259926, Phoenix, Arizona, United States
🇺🇸
University of California Irvine /ID# 260080, Irvine, California, United States

and more 145 locations

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Livmoniplimab
Drug: Atezolizumab
Drug: Durvalumab
Drug: Budigalimab
Drug: Tremelimumab
Drug: Bevacizumab

First Posted Date: 2023-10-31

Last Posted Date: 2024-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 660

Registration Number: NCT06109272

Locations: 🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 265506, Rome, Roma, Italy
🇺🇸
City of Hope /ID# 261468, Duarte, California, United States
🇺🇸
City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California, United States

and more 34 locations

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

Recruiting

Conditions: Parkinson's Disease (PD)

First Posted Date: 2023-10-30

Last Posted Date: 2024-12-13

Lead Sponsor: AbbVie

Target Recruit Count: 450

Registration Number: NCT06107426

Locations: 🇺🇸
Inland Northwest Research /ID# 253460, Spokane, Washington, United States
🇨🇦
The Ottawa Hospital - General Campus /ID# 263315, Ottawa, Ontario, Canada
🇦🇹
Medizinische Universitaet Innsbruck /ID# 262775, Innsbruck, Tirol, Austria

and more 33 locations

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2

Recruiting

Conditions: Unresectable Metastatic Colorectal Cancer

Interventions: Drug: ABBV-400
Drug: Bevacizumab
Drug: Folinic Acid
Drug: Fluorouracil
Drug: Irinotecan

First Posted Date: 2023-10-30

Last Posted Date: 2024-12-17

Lead Sponsor: AbbVie

Target Recruit Count: 206

Registration Number: NCT06107413

Locations: 🇧🇪
Universitair Ziekenhuis Leuven /ID# 257079, Leuven, Vlaams-Brabant, Belgium
🇺🇸
Highlands Oncology Group, PA /ID# 259424, Springdale, Arkansas, United States
🇺🇸
City of Hope National Medical Center /ID# 257576, Duarte, California, United States

and more 32 locations

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Phase 3

Recruiting

Conditions: Juvenile Psoriatic Arthritis

Interventions: Drug: Adalimumab
Drug: Risankizumab

First Posted Date: 2023-10-25

Last Posted Date: 2024-11-01

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT06100744

Locations: 🇺🇸
Arkansas Children's Hospital /ID# 258776, Little Rock, Arkansas, United States
🇺🇸
Joe Dimaggio Children's Hospital Hollywood /ID# 260634, Hollywood, Florida, United States
🇺🇸
Indiana University Health Riley Hospital for Children /ID# 259067, Indianapolis, Indiana, United States

and more 19 locations

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Phase 3

Withdrawn

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Telisotuzumab Vedotin
Drug: Cisplatin
Drug: Osimertinib
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2023-10-23

Last Posted Date: 2024-06-26

Lead Sponsor: AbbVie

Registration Number: NCT06093503

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma
Pancreatic Ductal Adenocarcinoma
Biliary Tract Cancers
Esophageal Squamous Cell Carcinoma
Triple Negative Breast Cancer
Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Head and Neck Squamous-Cell Carcinoma
Platinum Resistant High Grade Epithelial Ovarian Cancer

Interventions: Drug: ABBV-400

First Posted Date: 2023-10-16

Last Posted Date: 2024-11-25

Lead Sponsor: AbbVie

Target Recruit Count: 260

Registration Number: NCT06084481

Locations: 🇦🇺
Chris O'Brien Lifehouse /ID# 262765, Camperdown, New South Wales, Australia
🇮🇱
Rambam Health Care Campus /ID# 256649, Haifa, H_efa, Israel
🇵🇷
Pan American Center for Oncology Trials /ID# 262903, Rio Piedras, Puerto Rico

and more 50 locations

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers

Phase 1

Not yet recruiting

Conditions: Healthy Volunteers

Interventions: Drug: ABBV-903

First Posted Date: 2023-10-11

Last Posted Date: 2023-10-11

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT06078202

Locations: 🇺🇸
Acpru /Id# 259438, Grayslake, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy